PJPaul Jenkins

Paul Jenkins

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Paul Jenkins has a total of 127 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Determining essential priorities for future investigation - A national consensus exercise in Interventional Oncology (DEFINE-IO) – An a priori protocol

    by Vinson Wai-Shun Chan, Blair Graham, Helen Hoi-Lam Ng, Scott Griffiths, Deevia Kotecha, Hanif Ismail, Paul Jenkins, Jim Zhong, Raghuram Lakshminarayan, Tze Min Wah

    Introduction: Interventional Oncology (IO) is a rapidly developing subspecialty within interventional radiology (IR), offering minimally invasive, precise and targeted cancer therapies. Despite its transformative potential, IO faces challenges in identifying critical research priorities amidst limited funding and resources. The DEFINE-IO study aims to identify the most pressing research priorities in IO to guide researchers, policy makers, and funding bodies in driving innovation and improving cancer outcomes. Methods and analysis: This study comprises two phases: a modified e-Delphi process and a multi-criteria decision analysis (MCDA). The e-Delphi process will involve three rounds, with round 1 dedicated to generating research topics, followed by rounds 2 and 3, which will focus on refining and achieving consensus on the identified topics. The final consensus will yield a list of 25 research priorities, which will be evaluated during an in-person MCDA session. These priorities will be assessed against three predefined criteria: urgency, feasibility/equipoise, and affordability, to establish a strategic roadmap for research in IO. Ethics and dissemination: Formal ethics approval was deemed not necessary. Findings of the study will be presented at major conferences and published in a peer-reviewed journal. The findings will also be shared with funding bodies and policymakers to help guide future research directions.

  • An Overview of Interventional Pulmonary Embolism Management in the United Kingdom in 2026

    by D.C. Schramm, A. Morozow, I. Mandal, J. Lentaigne, P. Hughes, P. Jenkins

  • Open Access

    Identifying needs and setting priorities in research for vascular interventional radiology

    by Blair Graham, Paul Jenkins, Raghu Lakshminarayan, Nadeem Shaida, Lakshmi Ratnam, Jos Latour

  • Traumatic splenic injury in the elderly population: Does management choice affect outcome?

    by Paul Jenkins, Anton Barnett, Blair Graham, Yinji Tan, Lexy Sorrell, Jason Smith, Victoria Allgar, Carl Roobottom

    Purpose: Trauma within older people is increasingly recognised as a different entity, with different management and outcomes to younger people. We aim to compare the 30-day survival and length of stay of splenic injury patients in English major trauma centres in an elderly trauma (65+) cohort in comparison to under 65. Methods: Data were obtained from the Trauma Audit Research Network of all Grade 2–5 American Association of Surgery in Trauma (AAST) splenic injuries admitted to English Major Trauma Centres between 01/01/17 and 31/12/21. End-points of mortality and length of stay were compared between the under 65 and 65+ groups according to treatment using descriptive statistics and multi-variable regression analysis. Results: In total, 802/3958 (20.2%) of admissions were 65+ and 2926/3958 (73.9%) were male. The proportion of AAST grades 3–5 was 41.3% (331/802) for 65+ and 52.3% (1652/3156) for under 65. A total of 12.8% (103/802) received embolisation in the 65+ group and 13.1% (413/3156) within the under 65 group. In total, 6.9% (55/802) in the 65+ group received splenectomy compared to 10.1% (319/3156). Within the 65+ group, 30-day mortality in the splenectomy group was 14.5% (8/55) compared to embolisation (18/103, 17.5%) and conservative (141/644, 21.9%). The 30-day mortality was (10.3%, 33/319) in those having a splenectomy as first treatment in the under 65's, compared with embolisation (26/413, 6.3%) and conservative management (197/2424, 8.1%). Embolisation failure was 3.9% (4/103) in the 65+ group and 7.3% (30/413) in the under 65 group. Splenectomy is associated with an increased length of stay at 1.20 (confidence interval (CI) 1.06, 1.37) times longer; however, this was not affected by age group. Conclusion: Mortality was higher in the over 65 cohort regardless of treatment. Splenectomy is associated with an increased length of stay compared to embolisation, however there is no clear interaction demonstrated between age and first treatment.

  • Interventional Oncology Geographic Inequality—A Problem for Today

    by P. Jenkins, D. Velazquez-Pimentel, J. Pancholi, D. Kotecha, J. Zhong, P. Peddu, P. Littler, T. Wah

  • Time to Splenic Embolisation in Trauma Patients Arriving at a Major Trauma Centre In-Hours or Out-of-Hours: A UK Multicentre Study

    by P. Jenkins, A. See, A. Barnett, E. Wilson, D. Kotecha, L. Sorrell, V. Allgar, J. E. Smith, C. Roobottom

    Purpose To determine whether time of arrival at a major trauma centre (MTC) influences embolisation rate, time to embolisation, embolisation failure and 30-day survival in adult trauma patients. Materials and Methods Data for adults (> 18 years) admitted to an MTC and recorded in the UK Trauma Audit and Research Network database between 01/01/17 and 31/12/21 were analysed. ‘In-hours’ was defined as Monday to Friday (excluding holidays) 09:00–17:00; all other times were ‘out-of-hours’. Descriptive and regression analyses assessed factors associated with time to embolisation and 30-day survival, and the relationship between these outcomes. Results Among 2,560 patients with splenic injury (Abbreviated Injury Scale (AIS) > 2) directly admitted to an MTC, 184 (7.2%) underwent embolisation within 24 h. Of these, 79% were male (145/184) with a median age of 42 years (IQR 27–56). Embolisation within 24 h occurred in 48/600 (8.0%) of patients admitted in-hours versus 136/1,960 (6.9%) out-of-hours. Embolisation failure rate was similar between the groups (6.3% (3/48) in-hours versus 9.6% (13/136) out-of-hours). American Association for the Surgery of Trauma (AAST) grade and probability of survival were similar across groups. Median time to embolisation was 159 min (95% CI 142–213) in-hours and 238 min (95% CI 210–288) out-of-hours. After adjustment, out-of-hours patients had 1.34 times longer time to embolisation (95% CI 1.02–1.76). Regression analysis showed no strong association between time of admission and 30-day survival (odds ratio [OR] 2.13; 95% CI 0.76–5.81). Time to embolisation also showed no relationship with survival (OR 1.00; 95% CI 1.00–1.00). Conclusion Although out-of-hours presentation delayed embolisation, this did not affect 30-day survival, suggesting current trauma workflows maintain clinical effectiveness despite temporal disparities in interventional radiology (IR) access. Graphical Abstract


  • Open Access

    IO1-UK: a cross-sectional study to re-evaluate the provision of interventional oncology services across the United Kingdom

    by D. Velazquez-Pimentel, J. Pancholi, P. Jenkins, N. Cinti, M. Stephanou, D. Kotecha, A. White, S. Ashraf, O. Llewellyn, G. Vigneswaran, et al.

  • Open Access

    Determining Essential priorities for Future Investigation - a National consensus Exercise in Interventional Oncology (DEFINE-IO) – A priori protocol

    by Vinson Wai-Shun Chan, Blair Graham, Helen Hoi-Lam Ng, Scott Griffiths, Deevia Kotecha, Hanif Ismail, Paul Jenkins, Jim Zhong, Raghuram Lakshminarayan, Tze Min Wah

    Introduction: Interventional Oncology (IO), is a rapidly developing subspecialty within interventional radiology (IR), offering minimally invasive, precise and targeted cancer therapies. Despite its transformative potential, IO faces challenges in identifying critical research priorities amidst limited funding and resources. The DEFINE-IO study aims to identify the most pressing research priorities in IO to guide researchers, policy makers, and funding bodies in driving innovation and improving cancer outcomes. Methods and analysis: This study comprises two phases: a modified e-Delphi process and a multi-criteria decision analysis (MCDA). The e-Delphi process will involve three rounds, with round 1 dedicated to generating research topics, followed by rounds 2 and 3, which will focus on refining and achieving consensus on the identified topics. The final consensus will yield a list of 25 research priorities, which will be evaluated during an in-person MCDA session. These priorities will be assessed against three predefined criteria: urgency, feasibility/equipoise, and affordability, to establish a strategic roadmap for research in IO. Ethics and dissemination: Formal ethics approval was deemed not necessary. Findings of the study will be presented at major conferences and published in a peer-reviewed journal. The findings will also be shared with funding bodies and policymakers to help guide future research directions. Abstract Figure:

  • Pictorial review of the use of percutaneous mechanical thromboaspiration in peripheral vascular occlusions

    by H. Sabey-Corkindale, M. Finzel, R. Miles, N. Gafoor, M. Vasquez-Rios, M. Macanovic, S. Ghauri, P. Jenkins

  • Variation in paediatric splenic trauma management in adult and combined major trauma centres in England

    by H. Sanchez-Lewis, P. Jenkins, L. Sorrell, L. Watkins, J. Zhong, J.E. Smith, V. Allgar, C. Roobottom, I. Mccafferty